Equillium Inc
For the period ended Jun 30, 2024. Filed Aug 8, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2024 · Filed Aug 8, 2024
EQ$1.46-3.0%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Cash Flows
(In thousands)
| Six Months EndedJune 30, | ||
|---|---|---|
| 2024 | 2023 | |
| Operating activities: | ||
| Net loss | $(2,266) | $(7,283) |
| Adjustments to reconcile net loss to cash used in operating activities: | ||
| Depreciation | 67 | 62 |
| Stock-based compensation | 1,924 | 1,972 |
| Net unrealized loss on foreign currency transactions | 159 | 270 |
| Amortization of term loan discount and issuance costs | - | 180 |
| Amortization of investments, net | (519) | (597) |
| Deferred revenue | (7,298) | (4,882) |
| Changes in operating assets and liabilities: | ||
| Accounts receivable | (2,159) | (905) |
| Prepaid expenses and other current assets | 2,008 | (2,421) |
| Accounts payable | (203) | (930) |
| Accrued expenses | 228 | 332 |
| Right-of-use assets and lease liabilities, net | (11) | (8) |
| Net cash used in operating activities | (8,070) | (14,210) |
| Investing activities: | ||
| Purchases of property and equipment | (81) | - |
| Purchases of short-term investments | (17,601) | (37,181) |
| Maturities of short-term investments | 13,500 | 27,000 |
| Net cash used in investing activities | (4,182) | (10,181) |
| Financing activities: | ||
| Repayment of notes payable | - | (9,133) |
| Proceeds from issuance of common stock under employee stock purchase plan | 91 | 86 |
| Net cash provided by (used in) financing activities | 91 | (9,047) |
| Effect of exchange rate changes on cash and cash equivalents | 2 | (45) |
| Net decrease in cash and cash equivalents | (12,159) | (33,483) |
| Cash and cash equivalents at beginning of period | 23,216 | 59,107 |
| Cash and cash equivalents at end of period | $11,057 | $25,624 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.